Medivir AB (MVIRb.F), Daewoong Pharmaceutical Co., Ltd. Discontinue Hepatitis B Drug Development

Medivir: The Collaboration with Daewoong Pharmaceutical for the Development of the Hepatitis B Compound, MIV-210 Has Been Discontinued 

STOCKHOLM--(BUSINESS WIRE)-- Regulatory News: Medivir AB (MVIR-B.ST) today announced that it has discontinued the development of its hepatitis B compound MIV-210 based on a joint decision with Daewoong Pharmaceutical Co. Ltd., (South Korea). 

Under the terms of this collaboration agreement Daewoong has been responsible for the R&D work. MIV-210 has a demonstrably competitive antiviral activity but, like other drugs of this class, does not completely eradicate HBV. The commercial environment for HBV drugs, with the current standard of care approaching generic status, requires a robust cure profile. To achieve this cure profile would require combination with other drugs with different and new mechanisms. 

"In light of the characteristics MIV-210 could offer for the treatment of Hepatitis B, we have together with our partner Daewoong decided to abandon the development activities with MIV-210", said Maris Hartmanis, CEO, Medivir AB. 

About Medivir 

Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is simeprevir, a novel protease inhibitor in late phase III clinical development for hepatitis C that is being developed in collaboration with Janssen R&D Ireland. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics. 

For more information about Medivir AB, please visit the Company's website: www.medivir.com 

Medivir is a collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C. We are passionate and uncompromising in our mission to develop and commercialize innovative pharmaceuticals that improve people's health and quality of life. 

This information was brought to you by Cision http://news.cision.com 

Contact:

Medivir

Rein Piir, EVP Corporate Affairs & IR

Mobile: +46 708 537 292 

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.